SAB Biotherapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
SABS$3.07-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $20,519,724 | $10,502,680 |
| Short-term investments | 86,871,857 | 86,089,779 |
| Accrued interest receivable | 1,555,061 | 946,781 |
| Prepaid expenses and other current assets | 3,835,400 | 3,513,384 |
| Total current assets | 112,782,042 | 101,052,624 |
| Deferred issuance costs | — | 150,145 |
| Long-term prepaid assets | 5,279,709 | 5,309,345 |
| Long-term investments | 110,235,540 | 46,892,882 |
| Operating lease right-of-use assets | 2,885,331 | 2,603,059 |
| Financing lease right-of-use assets | 3,474,306 | 3,496,012 |
| Property, plant and equipment, net | 13,813,570 | 13,305,902 |
| Total assets | $248,470,498 | $172,809,969 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $3,544,958 | $3,145,805 |
| Accrued expenses and other current liabilities | 5,386,530 | 6,583,996 |
| Operating lease liabilities, current portion | 763,705 | 797,402 |
| Finance lease liabilities, current portion | 156,958 | 153,967 |
| Total current liabilities | 9,852,151 | 10,681,170 |
| Operating lease liabilities, noncurrent | 2,170,887 | 1,877,360 |
| Finance lease liabilities, noncurrent | 3,081,573 | 3,121,952 |
| Warrant liabilities | 6,117,586 | 5,635,112 |
| Total liabilities | 21,222,197 | 21,315,594 |
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity | ||
| Series A Preferred stock; $0.0001 par value; 10,000,000 shares authorized, 28,380 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 3 | 3 |
| Series B Preferred stock; $0.0001 par value; 2,928,570 shares authorized, 587,879 shares issued and outstanding at March 31, 2026 and 638,558 shares issued and outstanding as of December 31, 2025 | 59 | 64 |
| Common stock; $0.0001 par value; 800,000,000 shares authorized at March 31, 2026 and December 31, 2025; 75,799,241 and 47,664,564 shares issued at March 31, 2026 and December 31, 2025, respectively, and 75,744,576 and 47,609,899 outstanding at March 31, 2026 and December 31, 2025, respectively | 7,580 | 4,766 |
| Treasury stock, at cost; 54,665 shares held at March 31, 2026 and December 31, 2025, respectively | (5,521,246) | (5,521,246) |
| Additional paid-in capital | 362,748,721 | 267,719,445 |
| Accumulated other comprehensive income (loss) | (222,764) | 186,510 |
| Accumulated deficit | (129,764,052) | (110,895,167) |
| Total stockholders’ equity | 227,248,301 | 151,494,375 |
| Total liabilities and stockholders’ equity | $248,470,498 | $172,809,969 |
See accompanying notes to the condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.